Split History
ETFs Holding AVEO »    AVEO Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
AVEO Pharmaceuticals is a biopharmaceutical company. Co.'s product candidates include: tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody for the treatment of a potential treatment for squamous cell carcinoma of the head and neck, acute myeloid leukemia; AV-203, an anti-ErbB3 specific monoclonal antibody with high ErbB3 affinity; AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 an inhibitory antibody specific to Notch 3 a pathway in cell-to-cell communication. According to our AVEO split history records, AVEO Pharmaceuticals has had 1 split.
AVEO split history picture
AVEO Pharmaceuticals (AVEO) has 1 split in our AVEO split history database. The split for AVEO took place on February 20, 2020. This was a 1 for 10 reverse split, meaning for each 10 shares of AVEO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.

When a company such as AVEO Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the AVEO split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into AVEO Pharmaceuticals shares, starting with a $10,000 purchase of AVEO, presented on a split-history-adjusted basis factoring in the complete AVEO split history. AVEO split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 05/24/2010
End date: 05/22/2020
Start price/share: $78.90
End price/share: $9.47
Dividends collected/share: $0.00
Total return: -88.00%
Average Annual Total Return: -19.10%
Starting investment: $10,000.00
Ending investment: $1,200.14
Years: 10.00
Date Ratio
02/20/20201 for 10
AVEO is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

AVGR Split History
AVXL Split History
AYTU Split History
AZN Split History
BAX Split History
BCR Split History
BDMS Split History
BDX Split History
BGMD Split History
BIO Split History

Also explore: AVEO shares outstanding history

Laredo Petroleum, Inc. (LPI)
Global Eagle Entertainment Inc. (ENT)
ToughBuilt Industries, Inc. (TBLT)
Cyclacel Pharmaceuticals, Inc. (CYCC)
Chesapeake Energy Corporation (CHK)
Direxion Daily Gold Miners Index Bull 3X Shares (NUGT)
Direxion Zacks MLP High Income Index Shares (ZMLP)
Direxion Daily Retail Bull 3X Shares (RETL)
Direxion Daily Robotics, Artificial Intelligence & Automation Index Bull 3X Shares (UBOT)
Direxion Daily Junior Gold Miners Index Bull 3X Shares (JNUG)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

AVEO Insider Buying

AVEO Split History | www.SplitHistory.com | Copyright © 2013 - 2020, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.